Skip to main content
U.S. flag

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock (  ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Find more clinical trials

Arterial Spin Labeling (ASL) MRI for Cognitive Decline

Start: August 2012
End: May 2018
Enrollment: 120

What Is This Study About?

The purpose of this study is to determine the value of arterial spin labeling magnetic resonance imaging (ASL MRI), a measure of blood flow to the brain, in finding the cause of cognitive decline in people with mild cognitive impairment (MCI). Investigators will also compare ASL MRI to existing measures, in particular positron emission tomography (PET).

Do I Qualify To Participate in This Study?

Minimum Age: 55 Years

Maximum Age: 89 Years

Must have:

  • Fluent in English
  • Adequate seeing and hearing ability to allow for neuropsychological testing
  • Completed six grades of education
  • Geriatric Depression scale score of less than 6 (assessed within 3 months)
  • Women: Postmenopausal or surgically sterile
  • Participants with MCI:
    • MMSE between 24 and 30
    • Part of the longitudinal cohort of the Penn Memory Center/Alzheimer's Disease Clinical Cohort
    • Available study partner

Must NOT have:

  • Any significant neurological disease other than MCI
  • Presence of pacemakers, aneurysm clips, artificial heart valves, ear implants, metal fragments, or foreign bodies in the eyes, skin, or body; occupational risks for ferrous metal in the eye
  • Major depression, bipolar disorder, or history of schizophrenia
  • History of substance abuse or dependence within the past 2 years
  • Significant illness or unstable medical condition that could lead to difficulty complying with the protocol
  • Severe claustrophobia
  • Pregnancy
  • Clinically relevant abnormalities in prior blood or urine samples, including a blood glucose level of 180 mg/dl or higher
  • Prohibited medications: anticoagulants such as warfarin (Coumadin); other medical or drug treatment contraindicating protocol participation

If I Qualify, Who Do I Contact?

Contact study personnel listed either under the general study contact or the location nearest you.

Need Help?

Contact NIA’s Alzheimer’s and related Dementias Education and Referral (ADEAR) Center at 800-438-4380 or email ADEAR.

Where Is This Study Located?

Who Sponsors This Study?

Lead: University of Pennsylvania

Collaborator Sponsor

  • National Institute on Aging

Source: ClinicalTrials.gov ID: NCT01727622

alzheimers.gov

An official website of the U.S. government, managed by the National Institute on Aging at the National Institutes of Health